A Multi-center, Randomized, Controlled, Open-label Clinical Study to Evaluate the Efficacy and Safety of Mizoribine in Comparison With Cyclophosphamide in the Treatment of Refractory Nephrotic Syndrome
Phase of Trial: Phase III
Latest Information Update: 23 Jan 2019
Price : $35 *
At a glance
- Drugs Mizoribine (Primary) ; Cyclophosphamide
- Indications Nephrotic syndrome
- Focus Registrational; Therapeutic Use
- Sponsors Asahi Kasei
- 15 Jan 2019 Status changed from active, no longer recruiting to completed.
- 11 Jan 2018 Planned End Date changed from 1 Dec 2017 to 1 Nov 2018.
- 11 Jan 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Nov 2018.